Working… Menu

Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01521611
Recruitment Status : Completed
First Posted : January 30, 2012
Last Update Posted : April 8, 2019
Royal Free and University College Medical School
Information provided by (Responsible Party):
University Hospital Southampton NHS Foundation Trust

Brief Summary:
To determine whether a radiolabelled antibody that targets the bone marrow (the 'anti-CD66') can be administered safely to patients as part of the preparative treatment prior to haematopoietic stem cell transplantation ('a bone marrow transplant'). Can the radiolabelled antibody be shown to effectively target the bone marrow in these patients. If it can, could this result in better outcomes after transplantation.

Condition or disease Intervention/treatment Phase
Acute Leukaemia Chronic Leukaemia Myeloma Lymphoma Radiation: Targeted radiotherapy Phase 1 Phase 2

Detailed Description:

The aim of this clinical research study is to establish whether a radiolabelled antibody can be used to safely deliver radiotherapy to the bone marrow prior to stem cell transplantation for haematological malignancies.

With current chemotherapy regimens 60-90% of adult patients with acute leukaemia (AML and ALL) achieve a complete remission. However in a significant proportion of these patients the disease will recur. Although allogeneic and autologous bone marrow or peripheral blood haematopoietic stem cell transplantation (HSCT) are established as effective treatment options for haematological malignancies, resulting in long term disease free survival in a significant proportion of patients, the results of transplantation for patients with poor risk disease are disappointing. Further intensification of the treatment used prior to transplantation has been shown to reduce the risk of relapse, but the toxicity of the drugs or external beam radiotherapy causes an increase in transplant related deaths. The introduction of reduced intensity conditioning protocols allows the use of HSCT for older patients or those with significant additional medical problems but retrospective analysis indicates an increased rate of relapse. This is the 'Transplantation dilemma' - how to reduce the risk of disease relapse by intensifying therapy, but without an increase in toxicity to other organs causing an increase in transplant related deaths in remission.

Normal haematopoietic tissue and the malignant cells arising from it are very radiosensitive. Theoretically intensification of the conditioning therapy, particularly total body irradiation (TBI), prior to transplantation could increase tumour reduction leading to improved disease free survival rates for patients with poor risk disease. Targeted radiotherapy could allow treatment intensification without the toxicity to non-haematological tissues. In addition, the continuous, low dose rate delivered by the natural decay of a targeted radionuclide may have a greater destructive effect upon tumour cells than single dose or fractionated external beam radiation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Radiolabelled Anti-CD66 Monoclonal Antibody in the Conditioning Regimen Prior to Haematopoietic Stem Cell Transplantation: Phase I Study in Patients With Poor-risk Disease.
Actual Study Start Date : January 2002
Actual Primary Completion Date : July 1, 2017
Actual Study Completion Date : July 1, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Targeted radiotherapy
Patients receive therapy with an yttrium-90 labelled anti-CD66 following favourable dosimetry with the same antibody radiolabelled with indium-111.
Radiation: Targeted radiotherapy
Yttrium-90 labelled anti-CD66 monoclonal antibody.
Other Name: Y-90-anti-CD66

Primary Outcome Measures :
  1. Toxicities related to radiolabelled antibody. [ Time Frame: Up to 1 year post transplant World Health Organisation (WHO) toxicity criteria ]

    To determine the maximum tolerated dose (MTD) of targeted radiotherapy delivered by a murine anti-CD66 monoclonal antibody radiolabelled with yttrium-90 (Y-90) and determine the dose-limiting toxicity (DLT) in patients with haematological malignancies who are undergoing haematopoietic stem cell transplantation.

    Toxicities are assessed using WHO Toxicity Scale with 28 parameters.

Secondary Outcome Measures :
  1. Dosimetry model [ Time Frame: 5 days post infusion of an Indium-111 radiolabelled anti-CD66 ]
    Dosimetry is determined by whole body and SPECT-CT of the thorax and abdomen on days 1, 2, 4 and 5 post infusion of an indium-111 radiolabelled anti-CD66. Dosimetry determines whether patients proceed to therapy with the yttrium-90 labelled anti-CD66.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. An underlying haematological malignancy including acute myeloid leukaemia in first complete remission (CR1) but with poor prognostic features or in >CR1 or in relapse; acute lymphoblastic leukaemia; transformed myelodysplasia, chronic myeloid leukaemia (accelerated phase or blast transformation, poor response or intolerance of tyrosine kinase inhibitors), myeloma. Patients may be in remission, partial remission or relapse.
  2. No concurrent or recent (within 3 weeks) chemotherapy for the underlying haematological condition
  3. For patients with relapsed leukaemia, bone marrow (BM) blasts must represent < 20% of BM nucleated cells.
  4. Although the BM remission status is not important, patients must have cellularity > 10%.
  5. As malignant plasma cells may or may not express CD66 antigens, patients with myeloma must have less than 30% plasma cells (as a percentage of total nucleated cells) in the BM at the time of the study.
  6. Age = or >18 yrs.
  7. WHO performance status of 0, 1 or 2 (Appendix 5).
  8. Predicted life-expectancy of greater than four months.
  9. Patients must be negative for human anti-mouse antibodies (HAMA).
  10. Peripheral blood counts:

    Wbc < 30 x 10e9/l (absolute neutrophil count >0.5 x 10e9/L) platelets > 50 x 10e9/l (platelet support is permitted)

  11. Biochemical indices:

    Plasma creatinine < 120 micromol/l (or creatinine clearance or Ethylene diamine tetra acetic acid (EDTA) clearance > 50 ml/min) Plasma bilirubin < 30 micromol/l Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) no more than 2.5 x upper limit of the normal range.

  12. Patient must be able to provide written informed consent.

Exclusion Criteria:

  1. Any serious intercurrent disease.
  2. Patients with BM cellularity < 10%.
  3. History of atopic asthma, eczema or allergy to rodent protein, confirmed history of severe allergic reactions to penicillin or streptomycin.
  4. Positive Human anti-murine antibodies (HAMA).
  5. Patients unable to provide informed consent or who are unable to co-operate for reasons of poor mental or physical health.
  6. Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01521611

Layout table for location information
United Kingdom
Southampton University Hospitals NHS Trust
Southampton, Hampshire, United Kingdom, SO16 6YD
Royal Free Hospital and University College London
London, United Kingdom
Sponsors and Collaborators
University Hospital Southampton NHS Foundation Trust
Royal Free and University College Medical School
Layout table for investigator information
Principal Investigator: Kim H Orchard, MBBS PhD University Hospital Southampton NHS Foundation Trust

Layout table for additonal information
Responsible Party: University Hospital Southampton NHS Foundation Trust Identifier: NCT01521611     History of Changes
Other Study ID Numbers: RHMCAN0227
First Posted: January 30, 2012    Key Record Dates
Last Update Posted: April 8, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Trial fully recruited. Data will be summarised upon completion of study.
Keywords provided by University Hospital Southampton NHS Foundation Trust:
Bone Marrow Transplant (BMT)
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Immunologic Factors
Physiological Effects of Drugs